Cite
HARVARD Citation
Motzer, R. et al. (2022). Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet oncology. 23 (7), pp. 888-898. [Online].